Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1b/2 study of ASP2998 alone and with standard anticancer therapies in advanced solid tumors
jRCT2031250740Phase 2Recruiting
- Sponsor
- Astellas Pharma
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label trial of ASP2998 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), transitional cell carcinoma (TCC) and 3 more (7 arms), sponsored by Astellas Pharma. Primary endpoints: Dose-limiting toxicities and treatment-emergent adverse events, Clinical laboratory tests and 4 more. Started Mar 2026; status: recruiting.
02
Drugs
ASP2998
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)transitional cell carcinoma (TCC)gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on jRCT2031250740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250740.